Vernalis begins promoting MOXATAG Tablets in U.S.

Vernalis Therapeutics Inc. has initiated its promotion of MOXATAG Tablets to primary care physicians in the United States.

MOXATAG Tablets are a once-a-day combination therapy that uses the antibiotic amoxicillin. It is the only formulation of its kind to have FDA approval.

"We are excited to be promoting MOXATAG, the only once-daily formulation of the well-known antibiotic amoxicillin to physicians in the U.S. The benefit of taking one pill per day versus multiple times a day may represent an improvement in convenience for patients," Vernalis Therapeutics President and Chief Operating Officer said. "MOXATAG is a natural complement to our 12-hour codeine based prescription medication, TUZISTRA XR, as both products offer physicians and patients an extended-release alternative to existing treatments."

MOXATAG was approved by the FDA in 2008 and is an antibacterial medicine in the penicillin class developed to treat adult patients and pediatric patients 12 or older who have tonsillitis and pharyngitis secondary to Sterptococcus pyogenes (S. pyogenes).